BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Careful Connections: Building Association and Trust - 2Could the Star of Bethlehem have actually been a comet?
- 3Jersey's wellbeing score is below UK and France
- 4CDC's upcoming vote on hepatitis B vaccine could impact childhood immunization
- 5Who is Adm. Frank 'Mitch' Bradley and what does he have to do with the Venezuela boat strikes?
- Becoming amazing at Arranging Pay Raises
- Pentagon advances Golden Dome missile defense with new Space Force contracts
- Experience Is standing by: 10 Pleasant Setting up camp Areas to
- EU Council president: Ukraine should receive binding guarantees
- 4 injured in suburban Philadelphia nursing home explosion file negligence lawsuit
- Revvity says it will exceed 2025 profit forecast range
- 75% of US adults may meet criteria for obesity under new definition, study finds
- Don’t let food poisoning crash your Thanksgiving dinner
- Last Christmas, 3 million viewers watched a Chiefs love story — will Bills fans fall just as hard this year?
